StocksNeurogene Shares Surge After FDA Breakthrough Designation
Latest
Cullinan Therapeutics Insider Sells 8,000 Shares at $21.57
Jennifer Michaelson reduced her stake in Cullinan Therapeutics by 4.79% in a September sale, following a series of transactions this summer.
Champions Oncology Q1 2027 Results Miss Estimates
Champions Oncology reported a wider-than-expected loss and slightly lower revenue for the first quarter of 2027, highlighting continued operational challenges despite recent institutional interest.
Capricor Faces Fraud Suit Over Dermamiocel Data
Capricor Therapeutics is under investigation following a 64% single-day stock drop triggered by FDA disclosures regarding statistical analysis changes.
AtaiBeckley Q2 Loss Narrows as R&D Spend Surges
AtaiBeckley reported a narrower-than-expected Q2 loss, but revenue collapsed over 140% while research expenses more than doubled. Cash reserves remain sufficient for current operations.
NeuroPace beats Q2 estimates, lifts 2026 revenue outlook
NeuroPace delivered stronger-than-expected second-quarter results, driven by robust growth in its RNS System and a subsequent upward revision to its full-year financial guidance.
Tango Therapeutics Q2 Loss Widens Amid Rising Costs
Tango Therapeutics reported a wider-than-expected loss as expenses surged and collaboration revenue fell to zero following the conclusion of its Gilead partnership.
Roivant Shares Rise on Pulmonary Hypertension Data
Roivant Sciences shares climbed following positive clinical results for its pulmonary hypertension therapy, shifting investor focus to the durability of its clinical pipeline and commercial execution capabilities.
Kalaris Therapeutics Faces Dilution Risk Despite Solid Cash Runway
Kalaris Therapeutics holds $94m in cash with no debt, but rising burn rates threaten its runway.
Natera Sees Medicare Expansion Drive MRD Adoption
Natera reported new lymphoma data and Japanese regulatory approval, anchoring a valuation based on US$4.2b in projected 2029 revenue.
Monte Rosa Therapeutics Secures $50M Milestone as Novartis Starts Phase 2 Trial
Monte Rosa Therapeutics (GLUE) received a $50 million payment from Novartis, which has launched a Phase 2a/b trial for MRT-6160 in Sjögren’s disease, shifting clinical costs off the company's balance sheet.
Beta Bionics Faces Class Action Over Insulin Pump Safety Allegations
Beta Bionics faces a securities class action alleging that the company concealed serious device malfunctions and FDA violations, leading to a significant stock decline after public disclosures in early 2026.
Telix Faces FDA Decision Amid TGA Maggot Therapy Rule Changes
Telix Pharmaceuticals faces a critical FDA deadline for its glioma imaging agent, while Australian regulators ease requirements for maggot debridement therapy and diagnostic firms report lab progress.
More
Illustration: Tradingbird Mineralys Grants Inducement Awards to Two New Hires
Mineralys Therapeutics issued equity awards to two new non-executive employees under Nasdaq listing rules, adding to its compensation structure for key talent.
Illustration: Tradingbird Veracyte Shares Rise 3.3% Amid Insider Sales
Veracyte Inc shares climbed to $43.85, trading 12.7% above intrinsic estimates while insiders offload $22 million in stock.
Illustration: Tradingbird Capricor Faces Securities Suit Over Dermamiocel Plan Changes
A class action alleges Capricor misled investors regarding its statistical analysis plan for Dermamiocel, leading to a 64% stock drop.
Illustration: Tradingbird Alpha Cognition Issues 25,000 Inducement Options to New Hire
Alpha Cognition granted 25,000 stock options to a new non-executive employee under Nasdaq Rule 5635(c)(4), with an exercise price set at the September 8 closing rate.
Illustration: Tradingbird Cooper and Kewaunee Lead Post-Market Healthcare Moves
Cooper Companies and Kewaunee Scientific drove significant volatility in Wednesday's after-market session, with both names declining sharply following earnings releases.
Illustration: Tradingbird Pacira BioSciences issues inducement equity grants to five new hires
Pacira BioSciences disclosed the grant of stock options and restricted stock units to five new employees under Nasdaq Rule 5635(c)(4), with vesting schedules tied to continued service.
Illustration: Tradingbird Holmes Backer Raises $18M for New Blood Test Startup
Former Theranos CEO Elizabeth Holmes is advising a new $18 million blood-testing venture from prison, despite prominent investors declining to participate.
Illustration: Tradingbird X4 Pharmaceuticals Sets September Investor Meeting
X4 Pharmaceuticals will host a fireside chat at the 2026 Wells Fargo Healthcare Conference to discuss its pipeline and commercial strategy.
Illustration: Tradingbird Bloom Energy, Everpure, Illumina to Join S&P 500
Bloom Energy, Everpure, and Illumina are scheduled to enter the S&P 500 on September 21, replacing Molson Coors, The Trade Desk, and Builders FirstSource. While Bloom’s inclusion is driven by AI power demand, Illumina’s addition marks a significant upgrade to large-cap status following a revenue guidance raise and robust growth in clinical sequencing and AI-focused data services.